Researchers have discovered a new way that can potentially reduce the accumulation and spread of protein clumps known as Lewy bodies in a region of brain associated with Parkinson’s disease.
Parkinson’s is characterized by the loss of dopamine cells in the brain, primarily in a region called the substantia nigra pars compacta. It is in this area that Lewy bodies are found. Because the presence of Lewy body is associated with Parkinson’s symptoms, researchers are trying to figure out ways to eliminate the clumps.
Assia Shisheva, PhD, of Wayne State University School of Medicine in Detroit, and colleagues has been investigating the behavior of three proteins inside cells are involved with Parkinson’s. They are two enzymes, PIKfyve and Sac3, and a protein called ArPIKfyve.
The researchers discovered the proteins are involved in regulating material into the cells’ digestive system. In addition, the found out that if Sac3 is not bound to ArPIKfyve, it results in the death of the cell.
Also, mutations in Sac3 are linked to neurodegenerative disease, while mutations in PIKfyve are associated with a mild disease in the cornea of the eye.
The researchers conclude that the ArPIKfyve-Sac3 complex has separate functions in the brain, and the next step is to look for proteins that interact with it.
A new study provides fresh insights into a possible molecular method for reducing Lewy bodies — protein clumps found in the region of the brain that loses dopamine cells in people with Parkinson’s disease.
The research, from Wayne State University School of Medicine in Detroit, Mich., is published in The Journal of Biological Chemistry.
The dopamine-releasing cells most affected by Parkinson’s disease are located in a midbrain region known as the substantia nigra pars compacta. A hallmark of Parkinson’s disease is the accumulation and progressive spread of protein clumps called Lewy bodies in this region. Lewy bodies contain several proteins, the most common one is called alpha-synuclein.
Enjoying our content?
Thanks for visiting Psychiatry Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Psychiatry Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Evidence-Based Guidance
- Conference Coverage
- Unique Psychiatry Case Studies
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.